EZH2 moves

Epizyme Inc. and GlaxoSmithKline plc have independently reported small molecule inhibitors of histone methyltransferase enhancer of zeste homolog 2 that showed efficacy in preclinical models of lymphomas with activating mutations of the target.^1,2 Both companies plan to take inhibitors of the histone methyltransferase into the clinic in cancer.

Epizyme initially will focus on non-Hodgkin's lymphoma (NHL) patients with activating mutations in enhancer of zeste homolog 2 (EZH2). GSK declined to disclose how it will select a specific patient population. Neither company disclosed timing for an IND...